BSX · Earnings call · 2026Q3T · Full report

Market Demand Trends

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 49 · Surprise 32

Management described 2026 as a downturn after several years of exceptional growth, with EP and WATCHMAN now weighing on company growth. It said the remaining roughly 75% of the business has historically grown about 6% to 7%, citing interventional cardiology, vascular, IoE, and endoscopy as areas performing well despite China pressure. Management expects 2027 growth below the company’s approximately 7% WAMGR, with stabilization and improved growth targeted in 2028 as launches ramp.

Key facts